Please use this identifier to cite or link to this item:
Title: Recent advances in the understanding of severe cutaneous adverse reactions.
Austin Authors: Adler, N R;Aung, A K;Ergen, E N;Trubiano, Jason A ;Goh, M S Y;Phillips, Elizabeth J
Affiliation: Department of Medicine, Vanderbilt University Medical Centre, Nashville, TN, U.S.A..
School of Public Health & Preventive Medicine, Monash University, Melbourne, Victoria, Australia
Austin Health, Heidelberg, Victoria, Australia
The University of Melbourne, Melbourne, Victoria, Australia
Institute for Immunology and Infectious Diseases, Murdoch University, Murdoch, Western Australia, Australia
Department of Dermatology, University of Alabama, Birmingham, AL, U.S.A
Alfred Hospital, Melbourne, Victoria, Australia
Issue Date: Nov-2017 2017-09-29
Publication information: The British journal of dermatology 2017; 177(5): 1234-1247
Abstract: Severe cutaneous adverse reactions (SCARs) encompass a heterogeneous group of delayed hypersensitivity reactions, which are most frequently caused by drugs. Our understanding of several aspects of SCAR syndromes has evolved considerably over the last decade. This review explores evolving knowledge of the immunopathogenic mechanisms, pharmacogenomic associations, in vivo and ex vivo diagnostics for causality assessment, and medication cross-reactivity data related to SCAR syndromes. Given the rarity and severity of these diseases, multidisciplinary collaboration through large international, national and/or multicentre networks to collect prospective data on patients with SCAR syndromes should be prioritized. This will further enhance a systematized framework for translating epidemiological, clinical and immunopathogenetic advances into preventive efforts and improved outcomes for patients.
DOI: 10.1111/bjd.15423
ORCID: 0000-0002-7972-9050
PubMed URL: 28256714
Type: Journal Article
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Dec 5, 2022

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.